Values First Advisors Inc. Boosts Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

Values First Advisors Inc. grew its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) by 59.8% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,980 shares of the biopharmaceutical company’s stock after purchasing an additional 6,354 shares during the period. Values First Advisors Inc.’s holdings in Sage Therapeutics were worth $368,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in SAGE. Wellington Management Group LLP boosted its holdings in shares of Sage Therapeutics by 3.3% during the third quarter. Wellington Management Group LLP now owns 6,572,260 shares of the biopharmaceutical company’s stock valued at $135,257,000 after acquiring an additional 208,630 shares during the period. Algert Global LLC acquired a new stake in Sage Therapeutics in the 3rd quarter valued at about $1,167,000. Rafferty Asset Management LLC lifted its holdings in Sage Therapeutics by 197.1% in the 3rd quarter. Rafferty Asset Management LLC now owns 411,904 shares of the biopharmaceutical company’s stock valued at $8,477,000 after acquiring an additional 273,257 shares during the last quarter. Primecap Management Co. CA lifted its holdings in Sage Therapeutics by 41.3% in the 3rd quarter. Primecap Management Co. CA now owns 89,850 shares of the biopharmaceutical company’s stock valued at $1,849,000 after acquiring an additional 26,250 shares during the last quarter. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in Sage Therapeutics during the third quarter valued at about $8,052,000. Hedge funds and other institutional investors own 99.22% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have commented on SAGE shares. JPMorgan Chase & Co. upped their price objective on shares of Sage Therapeutics from $24.00 to $29.00 and gave the company an “overweight” rating in a research note on Tuesday. Stifel Nicolaus reduced their price objective on shares of Sage Therapeutics from $22.00 to $20.00 and set a “hold” rating for the company in a research note on Monday, December 18th. HC Wainwright upped their price objective on shares of Sage Therapeutics from $25.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, February 15th. Deutsche Bank Aktiengesellschaft assumed coverage on Sage Therapeutics in a report on Tuesday, December 12th. They issued a “hold” rating and a $21.00 target price on the stock. Finally, StockNews.com upgraded Sage Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, February 15th. Fifteen research analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and an average price target of $41.00.

Sage Therapeutics Stock Down 1.6 %

SAGE stock traded down $0.30 during midday trading on Thursday, hitting $18.74. 1,004,673 shares of the company traded hands, compared to its average volume of 963,600. Sage Therapeutics, Inc. has a twelve month low of $16.51 and a twelve month high of $59.99. The business has a 50 day simple moving average of $22.68 and a 200-day simple moving average of $21.40. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -2.07 and a beta of 0.87.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, beating the consensus estimate of ($1.28) by $0.73. Sage Therapeutics had a negative return on equity of 54.41% and a negative net margin of 626.32%. The company had revenue of $77.97 million during the quarter, compared to analysts’ expectations of $60.15 million. During the same period in the prior year, the business earned ($2.47) earnings per share. Sage Therapeutics’s revenue for the quarter was up 2621.5% compared to the same quarter last year. Equities research analysts forecast that Sage Therapeutics, Inc. will post -6.06 EPS for the current year.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.